Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 18/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154428 | 0.90 | ALDH1A1 (0.42) | P2RY1CYP1A2CYP2C9CYP2C19P2RY14 | |
| SCHEMBL3159741 | 0.85 | P2RY1 (0.35) | P2RY1P2RY14 | |
| SCHEMBL1135464 | 0.83 | P2RY1 (0.52) | P2RY1P2RY14 | |
| SCHEMBL1135717 | 0.80 | P2RY1 (0.39) | P2RY1P2RY14 | |
| SCHEMBL3151065 | 0.79 | ALDH1A1 (0.64) | P2RY1ALDH1A1 | |
| SCHEMBL3157705 | 0.77 | P2RY1 (0.40) | P2RY1P2RY14 | |
| SCHEMBL3158825 | 0.76 | P2RY1 (0.37) | P2RY1P2RY14 | |
| SCHEMBL3154143 | 0.74 | P2RY1 (0.36) | P2RY1P2RY14 | |
| SCHEMBL1936652 | 0.74 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5175474 | 0.72 | CYP1A2 (0.38) | P2RY1CYP1A2CYP2C9CYP2C19P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885CYP1A2 2831/4885CYP2C9 2190/4885 |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885CYP1A2 2831/4885CYP2C9 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.